The short version of 肠促胰素 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-08 and is reviewed periodically as new material appears.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
=== Institutional review boards (IRBs) === Approval by an Institutional Review Board (IRB), or Independent Ethics Committee (IEC), is necessary before all but the most informal research can begin. In commercial clinical trials, the study protocol is not approved by an IRB before the sponsor recruits sites to conduct the trial. However, the study protocol and procedures have been tailored to fit generic IRB submission requirements. In this case, and where there is no independent sponsor, each local site investigator submits the study protocol, the consent(s), the data collection forms, and supporting documentation to the local IRB. Universities and most hospitals have in-house IRBs. Other researchers (such as in walk-in clinics) use independent IRBs. The IRB scrutinizes the study both for medical safety and for protection of the patients involved in the study, before it allows the researcher to begin the study. It may require changes in study procedures or in the explanations given to the patient. A required yearly "continuing review" report from the investigator updates the IRB on the progress of the study and any new safety information related to the study.
=== Using a metal salt and cyclopentadienyl reagents === Sodium cyclopentadienide (NaCp) is the preferred reagent for these types of reactions. It is most easily obtained by the reaction of molten sodium and dicyclopentadiene. Traditionally, the starting point is the cracking of dicyclopentadiene, the dimer of cyclopentadiene. Cyclopentadiene is deprotonated by strong bases or alkali metals.
UPS' global hub for air shipments is the Worldport, located at Louisville Muhammad Ali International Airport. The facility contributes to the airport's status of the third-busiest cargo airport in the United States and the fifth-busiest worldwide. The Worldport consists of:
Sources: en.wikipedia.org
== Independent evaluation of the software == CASMI (Critical Assessment of Small Molecule Identification) is an open contest on the identification of small molecules from mass spectrometry data, and was launched in 2012 by Emma Schymanski and Steffen Neumann. In CASMI 2016, CSI:FingerID and a derivative of CSI:FingerID, in which the Böcker Group was also involved, won first and second place in the category "Best Automatic Structural Identification - In Silico Fragmentation Only". Also, CSI:FingerID had the best result for ranking the correct molecule structure at position one (70 out of 127, positive mode). In CASMI 2017, SIRIUS plus CSI:FingerID won in 3 of 4 categories: "Best Structure Identification on Natural Products", "Best Automatic Structural Identification - In Silico Fragmentation Only", "Best Automatic Candidate Ranking". In CASMI 2022, six out of 16 contestants used SIRIUS in their workflow to identify the best molecular structure candidates. SIRIUS won in the categories "Correct elemental formulas", "Correct compound structure classes" and "Correct 2D chemical structures". CASMI 2022 included compounds that were not even contained in PubChem.
== Nomenclature == This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 5,6,7,8-tetrahydropteridine:NAD(P)+ oxidoreductase. Other names in common use include 6,7-dihydropteridine:NAD(P)H oxidoreductase, DHPR, NAD(P)H:6,7-dihydropteridine oxidoreductase, NADH-dihydropteridine reductase, NADPH-dihydropteridine reductase, NADPH-specific dihydropteridine reductase, dihydropteridine (reduced nicotinamide adenine dinucleotide), reductase, dihydropteridine reductase, dihydropteridine reductase (NADH), and 5,6,7,8-tetrahydropteridine:NAD(P)H+ oxidoreductase.
== Applications == The SDS-PAGE in combination with a protein stain is widely used in biochemistry for the quick and exact separation and subsequent analysis of proteins. It has comparatively low instrument and reagent costs and is an easy-to-use method. Because of its low scalability, it is mostly used for analytical purposes and less for preparative purposes, especially when larger amounts of a protein are to be isolated. Additionally, SDS-PAGE is used in combination with the western blot for the determination of the presence of a specific protein in a mixture of proteins - or for the analysis of post-translational modifications. Post-translational modifications of proteins can lead to a different relative mobility (i.e. a band shift) or to a change in the binding of a detection antibody used in the western blot (i.e. a band disappears or appears). In mass spectrometry of proteins, SDS-PAGE is a widely used method for sample preparation prior to spectrometry, mostly using in-gel digestion. In regards to determining the molecular mass of a protein, the SDS-PAGE is a bit more exact than an analytical ultracentrifugation, but less exact than a mass spectrometry or - ignoring post-translational modifications - a calculation of the protein molecular mass from the DNA sequence. In medical diagnostics, SDS-PAGE is used as part of the HIV test and to evaluate proteinuria. In the HIV test, HIV proteins are separated by SDS-PAGE and subsequently detected by Western Blot with HIV-specific antibodies of the patient, if they are present in his blood serum.
Sources: en.wikipedia.org
Recurrent or high-risk basal cell and cutaneous squamous cell carcinomas in anatomically or cosmetically sensitive areas. Specific cases of early-stage or surface-level melanoma (melanoma in situ or lentigo maligna), and thin invasive melanoma in similarly sensitive sites. Other rare skin cancers where all the margins need to be visualized.
=== Articles === "Ending America's Endless War." Foreign Affairs, June 24, 2019 "Washington's Dangerous New Consensus on China." Foreign Affairs, June 17, 2021 "A Revolution in American Foreign Policy." Foreign Affairs, March 18, 2024 "Democrats must choose: The elites or the working class." The Boston Globe, November 10, 2024 "Bernie Sanders: Kennedy Must Resign." The New York Times, August 30, 2025
=== Tourism === Tourism is a major part of Hong Kong's economy, accounting for 5% of its GDP. In 2016, 26.6 million visitors contributed HK$258 billion (US$32.9 billion) to the territory, making Hong Kong the 14th-most popular destination for international tourists. It is the most popular Chinese city for tourists, receiving over 70% more visitors than its closest competitor Macau. The city is ranked as one of the most expensive cities for expatriates. However, since 2020, there has been a sharp decline in incoming visitors due to tight COVID-19 travel restrictions. In an attempt to attract tourists back to Hong Kong, the Hong Kong government announced plans to give away 500,000 free airline tickets in 2023. Hong Kong was the second most visited city in the world with 23.2 million visitors in 2025.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。